▎Edited by the WuXi AppTec content team
The rapid advancement of artificial intelligence (AI) is profoundly transforming the biopharmaceutical field in unprecedented ways.Some generative AI models have already been able to design proteins never before seen in nature, showcasing astonishing innovative potential.However, in the design of small-molecule drugs, AI faces more complex challenges — it not only needs to comprehensively balance molecular diversity but also must deeply understand medicinal chemistry and the intricate interactions between molecules and targets.Despite numerous technical challenges,Some startups are still boldly exploring the infinite possibilities of AI in small molecule drug design.Recently, the well-known industry media STAT selected five innovative companies leading this field, drawing significant attention from the industry.In today's article, the WuXi AppTec content team will provide a detailed introduction of these companies based on publicly available information.Terray Therapeutics is aIntegrating artificial intelligence, biology, medicinal chemistry, automation, and nanotechnology to advance drug discovery into the information ageBiotechnology Company。TerrayProprietary integrated computational and experimental platforms generate large-scale chemical data to accelerate drug discovery.In February 2022, Terray Therapeutics successfully raised $60 million in its Series A round.Financing, to advance its novel tNova platform and small molecule drug discovery based on it. In October this year, the company completed another $120 million in Series B financing.The funds raised will advance its internally developed pipeline, based on generative AI, into the clinical trial stage, and further enhance Terray's integrated AI platform, tNova, to support both internal and collaborative research and development projects.Terray Therapeutics is committed to accelerating the speed, reducing the cost, and increasing the success rate of small molecule drug development by integrating large-scale computing and novel data, thereby improving human health.The company has multiple artificial intelligence models that can both predict the properties of specific molecules and recommend molecules that meet multiple parameters through generative models.Relying on its proprietary experimental platform, Terray has built one of the world's largest chemical datasets, which has quantitatively measured over 5 billion target-ligand interactions in the past three years. This dataset is doubling in size each year.Terray's data advantage gives it the potential for "best-in-class" AI capabilities, which can identify and optimize new small molecules to solve complex problems.. The company has established multi-target partnerships with Bristol Myers Squibb and Calico.Cooperative Relationship, and has also established a partnership with Odyssey Therapeutics to jointly develop drugs targeting transcription factor targets.ItsThe internal product pipeline includes a multiple sclerosis treatment drug expected to enter clinical trials by 2026, with other candidates soon to follow.Iambic Therapeutics is a company dedicated to developing new therapies by leveraging an AI drug discovery platform.The company's platform combines physics and AI technology to identify drug candidates with differentiated drug characteristics.Currently, the company's main candidate drug IAM1363 has entered the clinical stage. This is a highly selective and brain-penetrant HER2 inhibitor. In addition, there areASelective CDK2/4 InhibitorIAM-C1 is about to enter the clinical development stage.。Iambic has two core artificial intelligence models:One model is NeuralPLexer, which can predict how protein and drug molecules interact and better handle proteins in different states.；Another model is Enchant, which can integrate molecular physical property data and clinical data to more accurately predict which drug properties will affect clinical outcomes.In terms of financing, Iambic completed a $53 million Series A funding round in 2021 and a $100 million oversubscribed Series B funding round in 2023. In June 2024, the company completed a $50 million Series B extension funding round. Earlier this year, Iambic advanced its HER2 inhibitor IAM1363 into clinical trials.The company expects to discuss the preliminary Phase 1 clinical data of IAM1363 in the first half of 2025 and anticipates advancing two additional oncology projects to the clinical stage soon.Genesis Therapeutics is a biotechnology company focused on artificial intelligence, leveraging its innovative generative predictive AI platform GEMS for the discovery of small molecule drugs.The GEMS platform integrates deep learning predictive models, molecular simulations, and chemically-aware language models., by generating potential molecules for synthesis and experimental testing, as well as iterating through multiple AI-powered cyclic processes, to accelerate the selection and optimization of candidate molecules.Genesis has established an internal R&D pipeline comprising multiple programs targeting those data-scarce and traditionally "undruggable" targets.In terms of strategic cooperation,Genesis reached a strategic cooperation agreement with Gilead Sciences in September this year to jointly discover and develop novel small-molecule therapies targeting three undisclosed targets.According to the agreement, Gilead paid Genesis a prepayment of $35 million. Previously, in 2022,Genesis Establishes Strategic Collaboration with Eli Lilly and Company to Develop Novel Therapies for Five Targets Across a Range of Therapeutic AreasGenesis thus received a prepayment of 20 million US dollars. In addition, in 2020,Genesis also signed a multi-target collaboration agreement with Genentech.。In GenesisWithin its internal product pipeline, the company has developed lead candidate drugs targeting immunology and advanced cancer.The specific timeline for when these candidate drugs will enter the clinical trial stage has not been disclosed.Isomorphic Labs, as a subsidiary of Alphabet,Its mission is to leverage artificial intelligence technology to accelerate the drug discovery process and ultimately find treatments for humanity's most devastating diseases, ushering in a new era of medical breakthroughs.。In an interview with STAT, the company's president, Colin Murdoch, mentioned,The company's technology stack includes predictive models that cover the entire lifecycle of drug discovery projects, as well as generative models capable of generating molecules for specific targets.。Although the company is currently focused on the development of small-molecule drugs, the discovery of novel targets is also part of the company’s future roadmap.Isomorphic has an internal drug pipeline (the therapeutic area has not been disclosed yet), and the company plans to collaborate with external partners for candidate drugs in the later stages of drug development. Additionally,The company has announced two collaborations with Eli Lilly and Novartis.Each collaboration has a potential value exceeding $1 billion, including milestone payments and royalties.Atomwise is a TechBio company dedicated to revolutionizing the field of small molecule drug discovery by leveraging AI and machine learning (ML) technologies.Atomwise Team Applies Deep Learning to Structure-Based Drug Design to Significantly Shorten the Drug Development Cycle。In terms of partnerships, Atomwise has reached cooperation agreements with several well-known companies.The company has signed agreements with Bayer for two crop protection projects and has also launched collaborations with companies such as Eli Lilly and Bridge Biotherapeutics.Multi-targetCooperationIn April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma to jointly develop innovative oncology drugs. In 2022, Atomwise further entered into a strategic and exclusive research collaboration with Sanofi.Agreement, receiving a $20 million upfront payment and is eligible to obtain milestone payments of up to $1 billion.In terms of product pipeline, Atomwise is advancing its proprietary small molecule candidate drug pipeline.One of the company's leading drug candidates is a TYK2 inhibitor, which was discovered through its proprietary AI platform, AtomNet.According to the company, AtomNet is an advanced neural network technology designed specifically for predicting the bioactivity of small molecules in structure-based drug discovery., its capability might even potentially replace traditional high-throughput screening methods.。With the continuous application of artificial intelligence technology in the biopharmaceutical fieldDeepen, whose potential in the process of new drug discovery and development is becoming increasingly significant. Looking ahead, we anticipate that these pioneering companies will continue to drive innovative transformations in the global health sector and make ongoing contributions to improving human health and well-being.▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
References:
[1]Using AI to design small
molecule drugs is tough. Here are five companies trying to crack the code，Retrieved December 6, 2024 from https://www.statnews.com/2024/12/03/who-to-know-series-biotech-companies-using-ai-small-molecules/
[2] Official Websites of Various Companies
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In ViewFocusing on Global Biomedical Health Innovation
